ORIC Filings — Oric Pharmaceuticals, Inc. - FilingSpy
ORIC
Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."
Rinzimetostat external costs more than doubled to $17.7M in Q2 2026 as ORIC prepares for a Phase 3 trial.
The cost of advancing rinzimetostat toward a Phase 3 trial is now the dominant driver of ORIC's financials. Net loss widened to $41.5M in Q2 2026 from $36.4M a year earlier as R&D expense rose 19% to $36.3M, with external costs for the lead candidate more than doubling to $17.7M. The company's cash runway extends into the second half of 2028, but the path to that date depends on a single pivotal trial.
Key takeaways
R&D expense rose 19% to $36.3M in Q2 2026, driven by an $8.6M increase in external costs for rinzimetostat, which reached $17.7M as the program advanced toward a Phase 3 trial expected to start in the first half of 2026.
The increase in rinzimetostat spending was partially offset by a $2.9M decline in external costs for enozertinib, the company's other lead candidate.
Net loss widened to $41.5M from $36.4M in Q2 2025, while other income rose $1.1M to $3.8M on higher interest income from the investment portfolio.
Section summaries
Management's Discussion and Analysis
R&D spend rose 19% YoY in Q2 2026 driven by rinzimetostat advancement; cash runway extends into 2H 2028.
⌄
Total operating expenses increased $6.2M to $45.3M in Q2 2026, driven by a $5.7M rise in R&D.
R&D growth was fueled by a $8.6M surge in external rinzimetostat costs, partially offset by a $2.9M decline in enozertinib spending.
Cash and equivalents fell 50.6% to $37.5M, but total cash, equivalents, and investments of $387.6M are expected to fund operations into the second half of 2028.
The company raised $59.9M in net proceeds from at-the-market equity offerings during the first half of 2026, and the reached $769.5M as of June 30, 2026.
What changed
The Phase 3 trial for rinzimetostat, flagged in the FY 2025 report as expected to start in H1 2026, has not yet been announced, though the sharp increase in external costs to $17.7M in Q2 2026 signals that preparatory activities are underway.
The cost savings from the August 2025 workforce reduction and pipeline prioritization are visible in G&A expenses, which rose only $0.5M to $9.0M, but the overall operating expense level continues to climb as rinzimetostat spending accelerates.
Enozertinib external costs declined $2.9M , a reversal from the prior trend of increasing investment, while no partnership readout from the J&J or Bayer agreements has been disclosed.
The company continued to draw on its at-the-market facility, raising $59.9M in H1 2026, consistent with the pattern of periodic equity raises flagged in prior quarters to extend the cash runway.
What to watch
Announcement of the rinzimetostat Phase 3 trial start, which was expected in H1 2026 per the FY 2025 report.
Q3 2026 and total cash, equivalents, and investments balance to gauge the burn rate against the 2H 2028 runway.
Any enozertinib partnership or Phase 3 development decision from the J&J or Bayer collaboration agreements.
Further at-the-market equity draws against the $200M facility as the company funds the Phase 3 trial.
General and administrative expenses rose modestly by $0.5M to $9.0M, primarily due to higher professional services.
Net loss widened to $41.5M from $36.4M in the prior-year quarter, with other income rising $1.1M on higher interest income.
The company raised $59.9M in net ATM proceeds during H1 2026 and expects its cash to fund operations into the second half of 2028.
Quantitative and Qualitative Disclosures About Market Risk
Interest rate risk is the primary market risk; a 100 bps rate change would not materially affect the $387.6M portfolio.
⌄
The company holds $387.6 million in cash, equivalents, and investments, mostly in money market funds, U.S. Treasury securities, and government-sponsored enterprise debt.
Investment policy targets principal preservation and liquidity, limiting maturities generally to less than two years.
A hypothetical immediate 100 change in interest rates would not have a material effect on the fair value of the portfolio.
The company does not believe inflation, interest rate changes, or exchange rate fluctuations significantly impacted results of operations for the periods presented.
From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material a…
⌄
From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
Clinical-stage biopharma with no approved products faces substantial doubt about funding, development, and regulatory success for its lead candidates rinzimetostat and enozertinib.
⌄
The company has a limited operating history, has never generated product , and expects to incur significant losses for years, with an of $769.5 million as of June 30, 2026.
Substantial additional capital is required to fund operations; existing cash of $387.6 million is only expected to last into the second half of 2028, and failure to raise funds could force delays or cuts to programs.
The business is substantially dependent on the success of two lead product candidates, rinzimetostat and enozertinib, which still require extensive clinical development and face intense competition from larger pharmaceutical companies.
A strategic pipeline reprioritization in August 2025 resulted in an approximately 20% workforce reduction, which may not yield expected cost savings and could disrupt operations and employee retention.
The company faces significant regulatory risks, including the lengthy and unpredictable FDA approval process, potential post-marketing requirements, and evolving healthcare laws like the Inflation Reduction Act that could pressure drug pricing.
Reliance on single-source third-party manufacturers, including those in China, exposes the company to supply chain disruptions from geopolitical tensions, tariffs, and trade restrictions.